SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Pitney Bowes amended its Credit Agreement on June 23, 2026, to provide an additional $150 million of incremental Term Loan A tranche, which was used to fund the redemption of $347 million of 6.875% Senior Notes due 2027. The transaction reflects an improved credit profile with new lender participation and represents a material refinancing of the company's debt structure.
View raw filing on EDGAR →Surf Air Mobility entered into a Master Subscription Agreement with Wheels Up for its Enterprise BrokerOS software, with an initial two-year term worth $8.0 million and an optional one-year extension worth $4.2 million (total up to $12 million). This represents a material commercial contract, strategic partnership, and significant revenue opportunity that validates the Company's software product.
View raw filing on EDGAR →Range Capital Acquisition Corp. issued an unsecured promissory note in the principal amount of up to $540,000 to its sponsor on June 18, 2026, to fund trust account contributions for the SPAC's business combination efforts.
View raw filing on EDGAR →Shareholders approved an amendment to the Company's Articles of Association extending the deadline for completing a business combination to 27 months from the IPO closing (December 23, 2024), with 11,660,851 shares voting in favor and 1,974,523 against; 9,339,529 ordinary shares were subsequently redeemed at approximately $10.62 per share, resulting in approximately $99.5 million in redemptions.
View raw filing on EDGAR →Jaguar Health executed the First Amendment to its Manufacturing and Supply Agreement with Woodward Specialty LLC, clarifying inventory management and title transfer procedures during an operational transition period through December 31, 2026.
View raw filing on EDGAR →The Company exercised its right to convert Series O Convertible Preferred Stock into common stock at a conversion ratio of 3.209 shares per preferred share, resulting in a material dilutive issuance of common stock that increases outstanding share count and dilutes existing common shareholders.
View raw filing on EDGAR →The filing discloses a proposed merger of Noble Africa LLC (ASP Isotopes' subsidiary holding Renergen Limited) with a subsidiary of ENDRA Life Sciences, with Noble Africa as the surviving entity and the combined company planning to list on Nasdaq. This is a material acquisition/change of control transaction. The concurrent $50 million private placement financing is integral to the transaction structure. The disclosure explicitly states the merger agreement terms, expected ownership structure (ASP ~89%, ENDRA ~3%, other investors ~7%), and anticipated closing in Q3-Q4 2026.
View raw filing on EDGAR →Clearwater Analytics completed an $8.4 billion take-private acquisition by a Permira and Warburg Pincus-led investor group on June 25, 2026. Stockholders received $24.55 per share in cash, and the company became a wholly owned subsidiary of the acquirer, resulting in delisting from the NYSE.
View raw filing on EDGAR →Concurrent with the merger closing, Clearwater entered into a new Credit Agreement providing $2.7 billion in senior secured term loans, $500 million in delayed draw term loans, and $325 million in revolving credit, totaling $3.525 billion in new direct financial obligations.
View raw filing on EDGAR →Effective upon the merger's consummation, the company amended its certificate of incorporation and bylaws, and the board of directors was reconstituted with director departures and appointments reflecting the change of control.
View raw filing on EDGAR →This exhibit announces a significant commercial expansion: MEDIROM MOTHER Labs has received an additional order from the Japan Ground Self-Defense Force (JGSDF) 8th Division that "triples" the deployment scale of its REMONY® remote health monitoring system. The announcement emphasizes the JGSDF's positive evaluation of the system's capabilities for heatstroke prevention and continuous health monitoring in harsh training environments. This represents a material operational and commercial milestone—a substantial expansion of an existing customer relationship with a government entity—that would affect a reasonable investor's assessment of the company's market traction and revenue prospects, though it does not fit the narrower categories of M&A, debt, or other specific event types.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the results of the Company's 2026 Annual Meeting of Stockholders held on June 23, 2026, including voting outcomes for two proposals: (1) election of directors Alexander Duka and Gary Kovacs as Class I directors, and (2) ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026. The detailed vote tallies (For, Against, Withhold, Abstain, Broker Non-Votes) are the core disclosure required by Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →The filing discloses the appointment of Pratik Trivedi as President and CEO effective July 6, 2026, along with his appointment to the Board, which is the principal disclosed action. While the filing also covers Kieran O'Sullivan's transition to Executive Chairman (a departure from CEO), the substantive focus and forward-looking impact center on Trivedi's appointment to the top executive role, including detailed compensation terms ($675,000 base salary, $2.15M long-term incentive award, and change-in-control severance provisions). This is a material executive succession event affecting investor assessment of company leadership.
View raw filing on EDGAR →This exhibit is a corporate presentation (investor deck) dated June 2026 disclosing Oculis' clinical development pipeline, preclinical and Phase 2 trial data for Privosegtor (optic neuritis neuroprotective candidate) and Licaminlimab (dry eye disease program), upcoming registrational milestones (PIONEER-1, PIONEER-2, PIONEER-3 trials), and financial position (cash runway into 2H 2029). The disclosure focuses on operational and clinical progress—trial designs, efficacy/safety results, regulatory designations (FDA Breakthrough, EMA PRIME, SPA agreement)—rather than a discrete event like M&A, executive change, or financial restatement. It is material because it updates investors on the status and timing of key value-driving clinical milestones and the company's pipeline advancement, which would affect a reasonable investor's assessment of the registrant's prospects.
View raw filing on EDGAR →The disclosure centers on amended and restated employment agreements for two named executives (CFO Conor Fennerty and Chief Investment Officer John Cattonar) that materially modify their compensation packages, including base salary increases ($600K→$650K and $500K→$550K), specified equity award targets (performance-based and time-based), and substantial backloaded restricted stock grants ($1.5M and $1.37M respectively with five-year vesting). This is a classic compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →26North BDC issued approximately 6.3 million shares of common stock on June 24, 2026, generating $156.2 million in gross proceeds pursuant to subscription agreements with investors. The issuance was made under exemptions from Securities Act registration (Section 4(a)(2), Regulation D, and Regulation S), relying on investor representations of accredited status or non-U.S. person status. This is a classic unregistered equity issuance disclosed under Item 3.02, materially dilutive to existing shareholders and a significant capital raise for the BDC.
View raw filing on EDGAR →SmartStop held its 2026 Annual Meeting of Stockholders on June 23, 2026, with shareholders voting on four proposals: election of six directors, advisory vote on executive compensation, frequency of future advisory votes on compensation, and ratification of BDO USA as independent auditor.
View raw filing on EDGAR →Public Storage closed a new $3.0 billion unsecured revolving credit facility, a $500 million delayed draw term loan facility, and established a $1.0 billion commercial paper program on June 25, 2026, replacing the prior $1.5 billion facility and materially enhancing the company's liquidity and financial flexibility. The new facilities total $4.5 billion in committed credit capacity and are governed by a Fourth Amended and Restated Credit Agreement with specified interest rates, maturity dates (2030-2031), and financial covenants.
View raw filing on EDGAR →This is a press release announcing Wise Group plc's full-year 2026 financial results, disclosing net revenue of $2.5 billion (up 19% YoY), income before tax of $660.4 million (26% margin), and FY2027 guidance. The document explicitly states "Wise Group plc reports Full Year 2026 Financial Results" and includes detailed financial metrics, quarterly breakdowns, and forward-looking guidance—all hallmarks of an earnings release. Material to investors as it discloses annual financial performance and strategic outlook.
View raw filing on EDGAR →Extra Space Storage LP entered into an underwriting agreement on June 24, 2026, to issue $550 million aggregate principal amount of 4.900% senior notes due 2032, fully guaranteed by the Company and certain subsidiaries. This is a material creation of a direct financial obligation through a public debt offering, with proceeds intended for repaying existing lines of credit, commercial paper, and general corporate purposes including acquisition funding. The transaction is clearly a debt issuance under Item 2.03 framework, disclosed here under Item 8.01.
View raw filing on EDGAR →Silver Point Specialty Lending Fund issued and sold 182,815 unregistered common shares for $5,000,000 pursuant to subscription agreements with shareholders, relying on Section 4(a)(2) of the Securities Act and Regulation D exemptions.
View raw filing on EDGAR →The Board of Trustees declared a regular monthly dividend of $0.24 per share payable to common shareholders as of June 30, 2026.
View raw filing on EDGAR →The filing discloses the declaration of regular and special distributions to shareholders of Class I, S, and D common shares, with specific per-share amounts ($0.21, $0.19136, and $0.20452 respectively) payable on or about July 31, 2026. This is a routine but material dividend distribution event typical of closed-end funds, affecting shareholder returns and capital allocation.
View raw filing on EDGAR →Mid-America Apartments, L.P. entered into a Term Loan Agreement on June 22, 2026, creating a new unsecured delayed draw term loan facility of up to $350 million (expandable to $550 million via accordion feature) maturing November 15, 2030. This is a material creation of direct financial obligation disclosed under Item 1.01, distinct from covenant breach or existing debt modification. The $350 million principal amount and syndicated lender group (KeyBank, Wells Fargo, TD Bank, JPMorgan Chase, and others) underscore materiality to a reasonable investor assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →The filing announces the expiration and final results of exchange offers whereby Accendra Health exchanged approximately $478.3 million of 2029 Notes and $548.0 million of 2030 Notes for newly issued First Lien Notes ($539.25 million total) and Second Lien Notes ($698.1 million), plus a separate New Money Notes Issuance of $326.25 million in First Lien Notes. This represents a material refinancing and creation of new direct financial obligations through debt issuance and exchange, affecting the company's capital structure and financial position.
View raw filing on EDGAR →Stifel issued a press release on June 25, 2026, disclosing selected operating results for May 31, 2026, including key performance metrics such as total client assets, fee-based client assets, loan balances, and treasury deposits. Although labeled as "operating data" rather than full earnings, the disclosure provides timely financial and operational metrics to investors and is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The CEO commentary on business performance and forward guidance further supports classification as an earnings-type disclosure.
View raw filing on EDGAR →The exhibit announces an amended and restated credit agreement dated June 24, 2026, extending the maturity of Enerflex's syndicated secured revolving credit facility (RCF) by three years to June 30, 2029, and increasing the accordion feature from $50 million to $200 million. While this is technically an amendment to an existing facility rather than a new issuance, it represents a material modification of the Company's direct financial obligations and credit structure. The extension of maturity and enhanced borrowing capacity are significant to the Company's financial flexibility and liquidity position, warranting classification as a debt-related event. The exhibit also announces the timing of Q2 2026 earnings release, but the primary material disclosure is the credit facility amendment.
View raw filing on EDGAR →ACRES Commercial Realty Corp. held its 2026 Annual Meeting of Stockholders on June 22, 2026, with voting results on five proposals: election of nine directors, advisory vote on named executive officer compensation, ratification of PricewaterhouseCoopers LLP as auditor, approval of approximately 7.5 million shares for the ACRES Capital Corp. merger, and adoption of the 2026 Omnibus Equity Incentive Plan.
View raw filing on EDGAR →Agilent closed the sale of $600 million in aggregate principal amount of 4.900% Senior Notes due 2032 on June 25, 2026, pursuant to a Purchase Agreement dated June 22, 2026. The issuance includes detailed terms covering the indenture, redemption provisions, covenants, and registration rights.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders. The filing reports final voting tallies for two proposals: election of three directors (H. Michael Schwartz, Stephen G. Muzzy, and Alexander S. Vellandi) and ratification of BDO USA, P.C. as independent auditor. All three directors were elected and the auditor appointment was ratified by substantial majorities, making this a material governance event that investors rely on to assess board composition and audit oversight.
View raw filing on EDGAR →Taysha entered into an underwriting agreement on June 24, 2026 to issue 32.5 million shares of common stock at $6.00 per share and 833,333 pre-funded warrants at $5.999 per warrant in a registered public offering, with expected net proceeds of approximately $187.4 million (or $215.6 million with full exercise of the underwriters' 30-day option). The offering is expected to fund operations into the second half of 2028.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the June 24, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes on three proposals: election of nine directors, ratification of Deloitte & Touche as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (shares for, against, withheld, abstained, and broker non-votes) for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →This exhibit presents the complete voting results from Cellectis S.A.'s Combined General Meeting of Shareholders, detailing 30 resolutions with vote tallies (For, Against, Vote Withhold), percentages, and quorum information. The resolutions cover material matters including approval of annual and consolidated financial statements, board director renewals, share buyback authorization, multiple capital increase delegations, and equity compensation authorizations. This is a classic shareholder_vote_results disclosure required under Item 5.07 equivalent for foreign private issuers.
View raw filing on EDGAR →Valerie Barnett, Chief Legal Officer and Corporate Secretary, is departing the Company effective June 29, 2026, following an agreement reached on June 18, 2026. This is a clear executive departure of a named officer. The filing explicitly states the termination date and confirms the separation is not due to disagreement, indicating an orderly transition. Departure of a C-suite officer is material to investors.
View raw filing on EDGAR →This Item 5.07 disclosure presents the results of Fulcrum's 2026 annual stockholder meeting held on June 24, 2026, including election of three Class I directors (Sonja Banks, Alan Ezekowitz, Colin Hill), advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The filing directly reports voting outcomes on these material governance matters, which is the core purpose of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →Devon Energy completed a settlement of exchange offers on June 25, 2026, issuing approximately $3.95 billion in aggregate principal amount of new senior notes across five series with maturities ranging from 2027 to 2055. The transaction involved entry into a Third Supplemental Indenture and creation of new direct financial obligations at the Devon Energy level.
View raw filing on EDGAR →The filing explicitly discloses a material cybersecurity incident under Item 1.05: unauthorized access to River Financial's network on June 16, 2026, with ransomware deployment discovered June 19, 2026. The company has taken containment measures and engaged third-party forensics to investigate potential personally identifiable information exfiltration. While the full impact remains under investigation, the incident has already impacted certain operations, making it material to investors assessing the registrant's operational continuity and data security posture.
View raw filing on EDGAR →TerrAscend issued $21.7 million in secured convertible debentures maturing September 30, 2031, at 8.00% interest, convertible into approximately 24.9 million common shares at $0.87 per share. The company used proceeds to retire higher-rate existing debt and retain capital for M&A purposes.
View raw filing on EDGAR →Heron Therapeutics received a written notice from Nasdaq on June 25, 2026, that its common shares failed to meet the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market. The company has been granted a 180-day compliance period (until December 22, 2026) to cure the deficiency, with potential for an additional 180-day period if certain conditions are met. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued market access.
View raw filing on EDGAR →This Item 5.07 discloses the final voting results from Coya Therapeutics' Annual Meeting of Stockholders held on June 25, 2026, including the election of two Class I directors (Secretary Wilbur Ross and Dieter Weinand) and ratification of Weaver and Tidwell, L.L.P. as independent auditor. The detailed vote tallies (For, Withheld, Broker Non-Votes, Against, Abstain) are the core disclosure required under Item 5.07 for shareholder meeting outcomes.
View raw filing on EDGAR →Ligand completed a $700 million issuance of 0.00% convertible senior notes due 2031 on June 25, 2026, in a private placement to qualified institutional buyers under Section 4(a)(2) and Rule 144A. The offering included convertible note hedge transactions and warrant transactions, with net proceeds of $678.2 million designated for general corporate purposes and share repurchases.
View raw filing on EDGAR →In connection with the convertible notes offering, Ligand issued warrants to purchase up to approximately 4.19 million shares of common stock, and the convertible notes may result in the issuance of up to 2.67 million shares upon conversion, representing a material dilutive capital raise through unregistered securities.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from ARS Pharmaceuticals' 2026 Annual Meeting held on June 24, 2026. The filing reports voting outcomes on four proposals: election of three Class III directors (Saqib Islam, Phillip Schneider, and Laura Shawver), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency (determined to be annual). These are standard annual meeting matters that materially inform investors about board composition and governance preferences.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Semnur Pharmaceuticals' 2026 Annual Meeting of Stockholders held on June 25, 2026. The filing reports the outcomes of four proposals: election of a Class I director (Jay Chun, M.D., Ph.D.), ratification of Pipara & Co LLP as independent auditor, approval of the 2025 Equity Incentive Plan, and approval of the 2025 Employee Stock Purchase Plan, with detailed vote tallies for each. This is a standard Item 5.07 disclosure of shareholder meeting results, which is material to investors as it confirms governance decisions and equity plan approvals.
View raw filing on EDGAR →Spero Therapeutics held its Annual Meeting on June 23, 2026, with stockholders voting on five matters: reelection of Class III directors (Milind Deshpande and Kathleen Tregoning), ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation, amendment to increase authorized common shares from 120 million to 240 million, and approval of the 2026 Stock Incentive Plan authorizing up to 12,895,866 shares for compensatory purposes.
View raw filing on EDGAR →Enova's subsidiary ODR 2022 amended its existing $420 million revolving receivables securitization facility on June 25, 2026, entering into Amendment No. 5 to the Credit Agreement. The amendment modifies material terms including borrowing rates, advance rates, and maturity dates extending to June 2029.
View raw filing on EDGAR →Apollo Debt Solutions BDC priced a $750 million offering of 6.350% notes due 2033 in a private placement to qualified institutional buyers. This is a material creation of a direct financial obligation through debt issuance, with the Fund expecting to use net proceeds for general corporate purposes and/or to repay existing indebtedness. The size and nature of the transaction clearly fall within the debt_issuance category.
View raw filing on EDGAR →This exhibit is a press release announcing OMS Energy Technologies Inc.'s fiscal year 2026 financial results for the year ended March 31, 2026. It discloses comprehensive financial metrics including revenues ($155.9M vs. $203.6M prior year), operating profit ($34.9M vs. $59.9M), net profit ($33.9M vs. $47.0M), operating cash flow ($54.1M), and EPS ($0.77 vs. $1.18), along with balance sheet and cash flow statements. The disclosure is material as it reports annual financial performance and would affect a reasonable investor's assessment of the registrant's financial condition and results of operations.
View raw filing on EDGAR →Live Oak Acquisition Corp. (a SPAC) completed a business combination with Teamshares Inc. on June 18, 2026, resulting in a change of control and the creation of a publicly traded combined company trading on Nasdaq under ticker 'TMS'. The transaction involved merger consideration of approximately $525 million, earnout provisions of up to 6 million shares contingent on stock price targets, PIPE investments, and forward purchase agreements.
View raw filing on EDGAR →In connection with the business combination, unregistered equity securities were issued including PIPE shares and contingent earnout shares (up to 6,000,000 shares) to Teamshares stockholders and optionholders, issued in reliance on Section 4(a)(2) exemption.
View raw filing on EDGAR →